NEW YORK (GenomeWeb News) – Hologic today announced the Netherlands Society for Pathology has approved the use of the Hologic Cervista HPV HR test in the Dutch national cervical screening program.

The National Institute for Public Health and the Environment in the Netherlands suggests routine pap testing and HPV HR triage for the ASCUS/LSIL (or atypical squamous cells of undetermined significance/ low-grade squamous intraepithelial lesion) testing for women over the age of 30 in order to identify those most likely to develop cervical cancer, Hologic said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.